Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3

Ishmael Jaiyesimi; Natasha B. Leighl; Nofisat Ismaila; Krishna Alluri; Narjust Florez; Shirish M. Gadgeel; Gregory A. Masters; Erin L. Schenk; Bryan J. Schneider; Lecia V. Sequist; Navneet Singh; Lyudmila Bazhenova; Elizabeth Blanchard; Janet Freeman‐Daily; Naoki Furuya; Balázs Halmos; Ibrahim Azar; Sara Kuruvilla; Michael P. Mullane; Jarushka Naidoo; Joshua E. Reuss; David R. Spigel; Dwight H. Owen; Jyoti D. Patel

doi:10.1200/jco.23.02746

Key Points

To update evidence-based clinical recommendations for first-, second-, and subsequent-line therapies in patients with stage IV non-small cell lung cancer lacking actionable driver alterations.
An expert panel reviewed emerging clinical trial evidence within the ASCO living guideline framework.
Therapeutic options were synthesized and graded specifically across initial and subsequent lines of systemic therapy.
Updated recommendations define preferred first-line systemic regimens for patients without actionable driver alterations.
Evidence-based therapeutic strategies are delineated for second-line and subsequent disease management following progression on prior therapies.

Implication

Clinical guideline reveals updated management recommendations in stage IV non-small cell lung cancer without driver alterations, highlighting optimized treatment sequences across lines of care.

Abstract

Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations.Additional information is available at www.asco.org/living-guidelines.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jaiyesimi et al. (2024) studied this question.

synapsesocial.com/papers/69d7485a58d71cbec648f642 https://doi.org/10.1200/jco.23.02746

View at Publisher

Ask AI

Bookmark

Share

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3

Key Points

Implication

Abstract

Discussion

Cite This Study

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading